The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter ...

Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...

The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared ...

NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...

Yes, you can get your flu and COVID-19 shots at the same time. Don’t call them boosters — they’re not just another dose of last year’s protection. The coronavirus and influenza are escape artists that ...

Recent health industry updates include AstraZeneca increasing its 2024 outlook, Cardinal Health's strategic investments, and ...